The Memo: DeepSight Technology Advancing Real-Time Interventional Imaging

Under the direction of Founder and CEO Nader Sadrzadeh, DeepSight Technology is redefining ultrasound for the interventional era. Based in Santa Clara at the heart of Silicon Valley with additional operations in Missouri, the company has developed proprietary sensor and imaging platforms that deliver crystal-clear, real-time visualization directly from inside the body. With its NeedleVue™ technology, DeepSight is positioning ultrasound not just as a diagnostic aid, but as a central guidance system for minimally invasive therapies.

Origin Story

DeepSight’s beginnings trace back to academic innovation. “DeepSight was founded on the strength of a remarkable technology developed by my co-founder, Dr. Lan Yang, at Washington University in St. Louis,” Sadrzadeh explained. He was introduced to Yang through Gaurav Garg at Wing Venture Capital, who ultimately became the company’s seed investor, board member, and a guiding force. “Together with Anand Chandrasheker, we saw that ultrasound was at a stall point and that we could go beyond these limitations by introducing our novel sensor technology.”

The team initially explored diagnostic applications, but their focus quickly shifted. “It became clear that the greatest immediate need, and the greatest opportunity for impact, was in interventional medicine,” Sadrzadeh said. “That realization led us to extend to therapeutic applications, where our technology could meaningfully transform the way procedures are performed.”

The Current Landscape

Procedures across specialties are becoming more complex, but imaging tools have not kept pace. “Every year, millions of patients undergo interventional procedures across radiology, oncology, cardiology, pulmonology, and other specialties; yet, physicians often lack reliable, real-time visualization of both anatomy and their instruments,” Sadrzadeh noted.

Today’s standards come with trade-offs. “Today, most interventional procedures rely on CT, fluoroscopy, and conventional ultrasound,” he said. “CT and fluoroscopy expose both patients and clinicians to harmful radiation, while conventional ultrasound, though safer, often lacks the clarity and navigation required for complex procedures.” Even when paired with electromagnetic sensing systems, ultrasound struggles to provide the precision, flexibility, and range of applications that modern interventions demand.

The result of these limitations is an increase in complications, longer procedures, and compromised outcomes. “As surgery shifts to minimally invasive, the need for real-time visualization has never been greater,” he emphasized.

Inside the Innovation

At the heart of DeepSight’s solution is a proprietary ultrasound sensor just 50 microns in size. “Our proprietary ultrasound sensor is microscopic, allowing it to be embedded into virtually any interventional instrument, including needles, guidewires, catheters, and even robotic systems,” Sadrzadeh said.

The company’s NeedleVue technology combines high-resolution ultrasound with precise instrument localization. “In addition to ultrasound imaging with precise localization, our system delivers an industry-first ultrasound feature we call OnPoint™ Imaging,” he explained. “This is an ultrasound ‘cockpit view’ of the local anatomy from the instrument tip. Imagine the power of ultrasound, Doppler, color flow, elastography, and more, all directly from the tip of any instrument inside the body. It’s truly amazing.”

Behind the scenes, enabling technologies like sweeping lasers, lasers-on-chip, and proprietary algorithms make this performance possible. The result is what Sadrzadeh calls Smart Instruments: intelligent, imaging-enabled tools that integrate seamlessly into existing workflows without added complexities.

“Every tool can now have eyes inside the body,” Sadrzadeh said.

Progress and Milestones

DeepSight has progressed from prototypes to real-world validation. The company recently secured its first FDA clearance for the NeedleVue Lite Cart system. Other past achievements include:

• Building a strong patent portfolio
• Securing its first OEM partnership
• Establishing collaborations with leading academic centers, including NIH, UNC, and more
• Conducting multiple clinical and GLP studies in partnership with IRCAD France
• Publishing and presenting data that demonstrate the overwhelming advantages of the technology

What sets DeepSight apart isn’t just the technology, but the people driving it. The company has built a world-class team of engineers, physicians, and industry experts, most recently welcoming Dr. Bradford Wood, former head of NIH Interventional Radiology and Interventional Oncology, as Vice President of Strategic Partnerships. “Bringing someone of his caliber, vision, and leadership onto the team further validates our mission and strengthens our ability to transform care and accelerate adoption,” Sadrzadeh said.

Looking ahead, DeepSight is preparing for additional FDA clearances, first-in-human studies, additional OEM partnerships, and a broad U.S. commercial launch, followed by global expansion.

The company is currently raising a Series C round. “This round takes us to the next level with commercialization and allows us to scale into the many applications our platform can address,” Sadrzadeh said. “Importantly, it carries us through to cash flow positive, which is a major inflection point for DeepSight.”

The LSI Effect

For Sadrzadeh, LSI plays a unique role in accelerating DeepSight’s trajectory. “LSI is special because it brings the entire medtech ecosystem into one room,” he said. “It’s not just networking at a singular event; it’s where meaningful, long-term partnerships can be built. For a company like ours, with a platform that touches so many areas of medicine, there’s no better place to tell our story and find the right allies.”

Join Us at LSI USA ‘26

Sadrzadeh has been selected to present at LSI USA ‘26 next March 16th–20th in front of hundreds of global medical technology companies. Join us in welcoming him to the event in Dana Point, CA, where he will share the latest updates on DeepSight’s technology and development.